Patient info Open main menu

Translarna 250 mg granules for oral suspension – patient leaflet, side effects, dosage

Last updated: · Text from the MHRA, as of · About this document

Medicine status: Prescription only (POM) ▼ Additional monitoring Details

Medicine strength:
250 mg
Contains active substance:
ATC code:
Similar medicines:

Patient leaflet - Translarna 250 mg granules for oral suspension

1. What Translarna is and what it is used for

Translarna is a medicine that contains the active substance ataluren.

Translarna is used to treat Duchenne muscular dystrophy resulting from a specific genetic defect that affects normal muscle function.

Translarna is used to treat patients aged 2 years and older, who are able to walk.

You or your child will have been tested by your doctor before starting treatment with Translarna, in order to confirm that your disease is suitable for treatment with this medicine.

How does Translarna work?

Duchenne muscular dystrophy is caused by genetic changes that result in an abnormality in a muscle protein called dystrophin which is needed for muscles to work properly. Translarna enables the production of working dystrophin and helps muscles work properly.

2. What you need to know before you take Translarna

Do not take Translarna

  • If you are allergic to ataluren or any of the other ingredients of this medicine (listed in section 6).
  • If you are receiving treatment with certain antibiotics, such as gentamicin, tobramycin, or streptomycin by injection into a vein.

Warnings and precautions

Your doctor must have done a blood test to confirm that your disease is suitable for treatment with Translarna. If you have any kidney problem, your doctor should check your kidney function regularly.

If you have severe kidney problems (eGFR <30 ml/min) or if you are receiving dialysis because your kidneys do not work (end-stage renal disease) your doctor will establish if treatment with Translarna is suitable for you.

Your doctor will test the levels of lipids (fats such as cholesterol and triglycerides) in your blood and your kidney function every 6 to 12 months. Your doctor will monitor your blood pressure every 6 months, if you are taking a corticosteroid medicine.

Children and adolescents

Do not give this medicine to children under the age of 2 years or weighing less than 12 kg, as there is not enough data in this group of patients.

Other medicines and Translarna

Tell your doctor if you are taking, have recently taken, or might take any other medicines. In particular do not take Translarna with the antibiotics gentamicin, tobramycin, or streptomycin given by injection. These may affect your kidney function.

Tell your doctor if you are taking any of the following medicines:

MedicineUsually prescribed for
acyclovirtreatment of chickenpox [varicella]
adefovirtreatment of chronic hepatitis B and/or HIV
atorvastatinlipid-lowering
benzylpenicillinsevere infections
bumetanidetreatment or prevention of congestive heart failure
captopriltreatment or prevention of congestive heart failure
ciprofloxacintreatment of infections
famotidinetreatment of active duodenal ulcer, gastroesophageal reflux disease
furosemidetreatment or prevention of congestive heart failure
methotrexaterheumatoid arthritis, psoriasis
olmesartanessential hypertension in adults
oseltamivirprevention of influenza
phenobarbitalsleep-inducing, prevention of seizures
pitavastatinlipid-lowering
pravastatinlipid-lowering
rifampicintreatment for tuberculosis
rosuvastatinlipid-lowering
sitagliptintype 2 diabetes
valsartantreatment or prevention of congestive heart failure

Some of these medicines were not tested together with Translarna and your doctor may decide to monitor you closely.

Pregnancy and breast-feeding

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine. If you become pregnant while taking Translarna, consult your doctor immediately as it is recommended not to take Translarna while you are pregnant or breast-feeding.

Driving and using machines

If you feel dizzy, do not drive, cycle or use machines.

3. How to take Translarna

Always take this medicine exactly as your doctor or pharmacist has told you. Check with them if you are not sure.

Translarna is available in the following sachet strengths: 125 mg, 250 mg and 1000 mg of ataluren per sachet. Your doctor or pharmacist will tell you the exact number of sachets and what strength to take at each time.

Your dose of Translarna depends on your body weight. The recommended dose is 10 mg/kg body weight in the morning, 10 mg/kg body weight at midday, and 20 mg/kg body weight in the evening (adding up to a total daily dose of 40 mg/kg body weight).

The medicine is taken by mouth mixed in liquid or semi-solid food.

Open the sachet only at the time you are taking the medicine and use the entire amount from the sachet. The full contents of each sachet should be mixed with at least 30 ml of liquid (water, milk, fruit juice) or 3 tablespoons of semi-solid food (yoghurt or apple sauce). Mix the prepared dose well before taking it. The amount of the liquid or semi-solid food can be increased based on your preference.

Posology table

Weight Range (kg)Number of Sachets
MorningMiddayEvening

125 mg

sachets

250 mg

sachets

1000 mg

sachets

125 mg sachets250 mg sachets

1000 mg

sachets

125 mg sachets250 mg sachets1000 mg sachets
1214100100010
1516100100110
1720010010010
2123010010110
2426010010020
2731010010120
3235110110120
3639110110030
4044110110130
4546020020130
4755020020001
5662020020011
6369030030011
7078030030021
7986030030031
8793001001031
94105001001002
106111001001012
112118011011012
119125011011022

Take Translarna by mouth 3 times per day; in the morning, midday and evening. There should be 6 hours between morning and midday doses, 6 hours between midday and evening doses, and 12 hours between the evening dose and the first dose on the next day. For example, you might take Translarna at 7:00 AM in the morning with breakfast, at 1:00 PM in the afternoon with lunch, and again at around 7:00 PM in the evening with dinner.

Drink water or other liquids regularly to avoid dehydration while taking Translarna.

If you take more Translarna than you should

Contact your doctor if you take more than the recommended dose of Translarna. You may experience mild headache, nausea, vomiting or diarrhoea.

If you forget to take Translarna

If you are late in taking Translarna by less than 3 hours after the morning or midday doses, or by less than 6 hours after the evening dose, take the dose. Remember to take the next dose on time. If you are late by more than 3 hours after the morning or midday doses, or by more than 6 hours after the evening dose, do not take the dose. But, take the next doses on time.

Do not take a double dose to make up for a forgotten dose. It is important to take the correct dose. Translarna may not be as effective in treating your symptoms if you take more than the recommended dose.

If you stop taking Translarna

Do not stop taking Translarna without talking to your doctor.

If you have any further questions on the use of this medicine, ask your doctor.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them. You may have one or more of the following side effects after taking Translarna:

Very common side effects (may affect more than 1 in 10 people):

  • Vomiting

Common side effects (may affect up to 1 in 10 people):

  • Decreased appetite
  • High blood triglyceride levels
  • Headache
  • Feeling sick
  • Weight loss
  • High blood pressure
  • Cough
  • Nosebleed
  • Constipation
  • Wind
  • Stomach discomfort
  • Stomach pain
  • Rash
  • Arm or leg pain
  • Chest pain
  • Involuntary urination
  • Blood in urine
  • Fever

Frequency not known (frequency cannot be estimated from the available data):

  • Increases in blood lipids
  • Increases in test for kidney function

Reporting of side effects

If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme. Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Translarna

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date, which is stated on the carton and sachet after ‘EXP’. The expiry date refers to the last day of that month.

This medicine does not require any special storage conditions.

Take each prepared dose immediately after preparation. Discard the prepared dose if not taken within 24 hours of preparation if kept refrigerated (2 – 8 °C), or within 3 hours at room temperature (15 - 30 °C).

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What Translarna contains

Translarna is available in 3 strengths, each containing 125 mg, 250 mg and 1000 mg of the active substance, called ataluren. The other ingredients are: polydextrose (E1200), macrogol, poloxamer, mannitol (E421), crospovidone, hydroxyethyl cellulose, artificial vanilla flavour (maltodextrin, artificial flavours and propylene glycol), silica, colloidal anhydrous (E551), magnesium stearate.

What Translarna looks like and contents of the pack

Translarna is white to off-white granules for oral suspension in sachets.

Translarna is available in packs containing 30 sachets.

Marketing Authorisation Holder and Manufacturer

PTC Therapeutics International Limited

Unit 1,

52-55 Sir John Rogerson’s Quay,

Dublin 2, D02 NA07

Ireland

This leaflet was last revised in 06/2025

This medicine has been given ‘conditional approval’. This means that there is more evidence to come about this medicine.

The Medicines and Healthcare Products Regulatory Agency will review new information on this medicine at least every year and this leaflet will be updated as necessary.

Detailed information on this medicine is available on the Medicines and Healthcare Products Regulatory Agency web site: http://www.mhra.gov.uk There are also links to other websites about rare diseases and treatments.

About this document

Source: MHRA - Medicines and Healthcare products Regulatory Agency (products.mhra.gov.uk) · Marketing authorisation: PLGB 44221/0004

Last revision stated in the text: June 2025 · MHRA data as of 13 October 2026

Found a mistake? Tell us on the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Facts about Translarna 250 mg granules for oral suspension

Prescription needed? Yes, prescription-only medicine (POM)
Active substance Ataluren
Strength 250 mg
Pharmaceutical form Granules for oral suspension
White to off-white granules.
How is it taken Oral
Excipients Polydextrose (E1200), Macrogol, Poloxamer, Mannitol (E421), Crospovidone, Hydroxyethyl cellulose, Artificial vanilla flavour: maltodextrin, artificial flavours and propylene glycol., Silica, colloidal anhydrous (E551), Magnesium stearate
Pack sizes 30 sachet
Is it available? Listed as available (NHS Dictionary of Medicines and Devices – not a record of current supplies)
Shelf life 4 years
Each prepared dose is best administered immediately after preparation. The prepared dose should be discarded if not consumed within 24 hours of preparation if kept refrigerated (2 – 8 °C), or within 3 hours at room temperature (15 – 30 °C).
Storage This medicinal product does not require any special storage conditions. For storage conditions after dilution of the medicinal product, see section 6.3.
Drug group (ATC) Other drugs for disorders of the musculo-skeletal system
  1. M Musculo-skeletal system drugs
    1. M09 Other drugs for disorders of the musculo-skeletal system
      1. M09A Other drugs for disorders of the musculo-skeletal system
        1. M09AX Other drugs for disorders of the musculo-skeletal system
          1. M09AX03 ataluren
Additional monitoring Yes ▼ – new safety information is collected quickly. Report any side effect to the Yellow Card scheme.
Marketing authorisation PLGB 44221/0004 (first authorised 24 February 2026)
Marketing authorisation holder PTC Therapeutics International Limited
Codes GTIN 3400927959202, 5391528831111 · BNF 10020300

Sources: the MHRA product information (products.mhra.gov.uk) and the NHS Dictionary of Medicines and Devices (dm+d), release 10.2.0 of 19 October 2026, NHS Business Services Authority. Contains public sector information licensed under the Open Government Licence v3.0.